Keros Therapeutics (NASDAQ:KROS) stock plunged 73% Thursday after the company said it has halted two arms of a Phase 2 clinical study of its drug cibotercept in patients with pulmonary arterial ...

Your liver filters everything that goes into your body. It clears out alcohol, drugs, and chemicals from your blood. Then it processes the unwanted bits so you can flush them out through your ...

With sup­ply short­ages fad­ing and new in­di­ca­tions grow­ing, the main ques­tion for obe­si­ty drug­mak­ers en­ter­ing the new year is what they’ll try and treat next … ...

A recent study published in the Hypertension journal highlights the cost-effectiveness of salt substitution over antihypertensive drug treatment in managing prehypertension among Chinese adults, ...

Fentanyl has made headlines for driving overdose deaths, but the Centers for Disease Control and Prevention (CDC) is warning of the rise of an even deadlier drug. Last year, nearly 70% of all U.S.

Drug resistance to currently available treatments only worsen the problem. Drug discovery is expensive and time-consuming, making drug repurposing an enticing option. Emodepside, a broad-spectrum ...

Warnings have been issued over commonly prescribed drugs could increase risk of dementia following a scientific study. Research suggested that regular use of certain types of commonly-prescribed ...

(NASDAQ:APLT), a pharmaceutical company with a market capitalization of $203 million, is currently addressing concerns from the U.S. Food and Drug Administration ... clinical study, AT-007-1002.

But if that's not enough to convince you, our latest study suggests CrossFit's benefits for physical health may even potentially reduce the need to use prescription drugs in people living with ...

Drug overdose deaths in the United States fell ... At least one important study has found that it may be less deadly than injecting fentanyl. Some people are also using methamphetamine instead ...

Dec 2 (Reuters) - Applied Therapeutics (APLT.O), opens new tab said on Monday it received a warning letter limited to a trial studying its genetic disease drug, after the U.S. health regulator ...